Zacks Investment Research upgraded shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) from a hold rating to a buy rating in a research report released on Tuesday. Zacks Investment Research currently has $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

RTTR has been the topic of a number of other research reports. Maxim Group reissued a hold rating on shares of Ritter Pharmaceuticals in a research note on Wednesday, July 5th. Chardan Capital lowered their price objective on Ritter Pharmaceuticals from $3.50 to $1.50 and set a buy rating on the stock in a research note on Tuesday, August 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $4.88.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 0.56 on Tuesday. The company’s market capitalization is $8.26 million. The stock has a 50 day moving average of $0.57 and a 200-day moving average of $1.23. Ritter Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.14). On average, equities research analysts anticipate that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Ritter Pharmaceuticals, Inc. (RTTR) Upgraded to “Buy” by Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/ritter-pharmaceuticals-inc-rttr-upgraded-to-buy-by-zacks-investment-research/1531402.html.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. increased its stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 7.62% of the company’s stock.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.